Karen Elaine Wittmer, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1045 4th Ave Pioneer Bldg, New Kensington, PA 15068 Phone: 724-335-9883 Fax: 724-335-2867 |
Christine Eller, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 113 Ridge View Rd, New Kensington, PA 15068 Phone: 412-795-8865 |
Gabrielle Heidenreich, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1045 4th Avenue, New Kensington, PA 15068 Phone: 724-335-9883 |
Sheri Lynn Gonder, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1045 4th Avenue, New Kensington, PA 15068 Phone: 724-895-8216 |
Mariah Lynnay Webb, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1045 4th Avenue, New Kensington, PA 15068 Phone: 724-859-8217 |
Kelly Lundstrom, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1045 Fourth Avenue, New Kensington, PA 15068 Phone: 724-335-9883 |
Melanie Dickman, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1045 4th Ave, New Kensington, PA 15068 Phone: 724-335-9883 |
News Archive
Scientists of the Institute of Structural Biology of Helmholtz Zentrum München and the Technische Universität München have succeeded in elucidating the structure of an important region of the Sam68 protein. Sam68 is a key protein for cellular signal transduction. The Journal of Biological Chemistry has selected the report of these research findings as one of two "papers of the week" for its September 10, 2010 issue and has chosen the structural model as cover image.
Testing for the human papillomavirus (HPV) - the major cause of cervical cancer - may not help to identify women who are at risk of the disease, a new UK study suggests.
One consequence of the expanded access to health care facilitated by health care reform will be a shortfall in the necessary numbers of physicians and other advanced medical professionals.
Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.
› Verified 7 days ago